Page last updated: 2024-11-13

gsk525762a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

molibresib: mimicks acetylated histones; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46943432
CHEMBL ID1232461
CHEBI ID95082
SCHEMBL ID1872390
MeSH IDM0553168

Synonyms (63)

Synonym
HY-13032
bet inhibitor gsk525762
gsk525762
i-bet 762
gsk-525762
molibresib
gsk-525762a
CHEMBL1232461 ,
gsk525762a
2-[(4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide
EAM ,
bdbm50365463
SCHEMBL1872390
NCGC00263621-02
2YEK
CS-0717 ,
S7189 ,
gtpl7033
i-bet-762
i-bet762
CCG-208698
2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-n-ethylacetamide
AAAQFGUYHFJNHI-SFHVURJKSA-N
gsk 525762a
1260907-17-2
3P5O
(s)-2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-n-ethylacetamide
unii-5qio6srz2r
(4s)-6-(4-chlorophenyl)-n-ethyl-8-methoxy-1-methyl-4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-4-acetamide
4h-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-4-acetamide, 6-(4-chlorophenyl)-n-ethyl-8-methoxy-1-methyl-, (4s)-
molibresib [usan]
molibresib [who-dd]
molibresib [inn]
2-((4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4hbenzo(f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-4-yl)-n-ethylacetamide
5QIO6SRZ2R ,
AC-32712
AKOS025404837
J-005327
DTXSID60677590
EX-A462
gsk-525762a (i-bet 762)
CHEBI:95082
BP-23442
i-bet762, >=98% (hplc)
NCGC00263621-04
(s)-2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-benzo-[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-n-ethylacetamide
SW220225-1
2-((4s)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepin-4-yl)-n-ethylacetamide
BCP07337
mfcd22417091
Q27078016
AS-16364
molibresib (usan)
D11326
gsk-525762a(i-bet-762)
(4s)-6-(4-chlorophenyl)-n-ethyl-8-methoxy-1-methyl-4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide
nsc-774829
nsc774829
4h-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine-4-acetamide, 6-(4-chlorophenyl)-n-ethyl-8-methoxy-1-methyl-, (4s)-
NCGC00263621-06
molibresib (i-bet-762)
2-[(7s)-9-(4-chlorophenyl)-12-methoxy-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0,2,6]tetradeca-1(10),3,5,8,11,13-hexaen-7-yl]-n-ethylacetamide
EN300-20050078

Research Excerpts

Effects

ExcerptReferenceRelevance
"GSK525762A has a similar effect on Ph⁺ ALL and Ph⁻ B-ALL, but the effect of proliferation inhibition and apoptosis enhancement on Ph+ B-ALL is weaker than that on Ph⁻ B-ALL."( [In vitro study of BRD4 inhibitor GSK525762A against primary adult common B-cell acute lymphoblastic leukemia cells in vitro].
Cao, J; Chen, C; Li, Y; Ma, S; Song, X; Wang, X; Xu, K; Zhu, J, 2015
)
1.42

Actions

GSK525762A could inhibit the proliferation of leukemia cells from all 14 common B-ALL patients in a dose-dependent manner. The median value of IC50 was 256.25 (90.64-1 378.39)nmol/L.

ExcerptReferenceRelevance
"GSK525762A can inhibit the proliferation of RS4; 11 cells and promoted cells apoptosis. "( [Effect of bromdomain protein 4 inhibitor GSK525762A on the proliferation and apoptosis of B-cell acute lymphoblastic leukemia cells and its mechanism].
Chen, C; Song, X; Wang, L; Wang, M; Xu, J; Xu, K; Zeng, L; Zhang, H, 2014
)
2.11
"GSK525762A could inhibit the proliferation of leukemia cells from all 14 common B-ALL patients in a dose-dependent manner, the median value of IC50 was 256.25 (90.64-1 378.39)nmol/L. "( [In vitro study of BRD4 inhibitor GSK525762A against primary adult common B-cell acute lymphoblastic leukemia cells in vitro].
Cao, J; Chen, C; Li, Y; Ma, S; Song, X; Wang, X; Xu, K; Zhu, J, 2015
)
2.14
"GSK525762A could inhibit significantly SUP-B15 cell proliteration in dose-and time-dependent manner; GSK525762A treatment could induce apoptosis of SUP-B15 cells. "( [Effect of BRD4 Inhibitor GSK525762A on Proliferation and Apoptosis of SUP-B15 Cells In Vitro and Its Possible Mechanism].
Chen, C; Ma, S; Qi, N; Wang, L; Wang, X; Wu, QY; Xu, KL; Yan, ZL, 2016
)
2.18

Treatment

ExcerptReferenceRelevance
"GSK525762A treatment could induce apoptosis of KU812 cells in a dose-dependent manner."( [Effect of BRD4 inhibitor GSK525762A on proliferation and apoptosis of KU812 leukemic cells and its mechanism].
Chen, C; Han, ZX; Song, XG; Wang, L; Wu, QY; Xu, J; Xu, KL; Zeng, LY; Zhao, K, 2014
)
1.42

Toxicity

ExcerptReferenceRelevance
" In the first-time-in-human BET115521 study of molibresib in patients with solid tumors, thrombocytopenia was the most frequent treatment-related adverse event (AE), QT prolongation was an AE of special interest based on preclinical signals, and gastrointestinal (GI) AEs (nausea, vomiting, diarrhea, and dysgeusia) were often observed."( Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.
Bergsma, T; Dhar, A; Ferron-Brady, G; Hanze, E; Krishnatry, AS; Prohn, M, 2022
)
0.72
" The primary safety endpoints were incidence of adverse events (AEs) and serious AEs; the primary efficacy endpoint was overall response rate."( Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Azad, AA; Blay, JY; Cassier, PA; Cousin, S; Datta, A; de Bono, JS; Dhar, A; Ferron-Brady, G; Foley, SW; French, CA; Garcia, IB; Hann, CL; Hemming, ML; Horner, T; Im, SA; Italiano, A; Keedy, VL; Khaled, A; Kremer, BE; Le Tourneau, C; McCabe, MT; Moreno, V; O'Dwyer, PJ; Piha-Paul, SA; Plummer, R; Sablin, MP; Shapiro, GI; Trigo, J; Wu, Y; Wyce, A, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" To enable administering safe doses of molibresib to healthy volunteers, this 2-part randomized, open-label, crossover drug-drug interaction trial was conducted as an adaptive design study using physiologically based pharmacokinetic (PBPK) modeling and simulation to predict the lowest doses of molibresib that could be safely administered alone (10 mg) or with itraconazole and rifampicin (strong inhibitors and inducers of CYP3A and P-gp, respectively)."( An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Collins, G; Ferron-Brady, G; Kremer, BE; Patel, A; Riddell, K; Schramek, D; Zhou, Y, 2021
)
0.62
" The molibresib pharmacokinetic (PK) profile has been characterized by a decrease in exposure over time, with the decrease more pronounced at higher doses, and accompanied by a slight increase of the metabolite concentrations."( Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.
Dhar, A; Ferron-Brady, G; Krishnatry, AS; Prohn, M; Voelkner, A, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" Notably, compound 85 demonstrated a reasonable antiproliferation effect on MV4;11 leukemia cells and exhibited a good pharmacokinetic profile with high oral bioavailability (75."( Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
Ding, K; Liu, Z; Song, M; Tu, Z; Wang, Z; Xiang, Q; Xing, Y; Xu, Y; Xue, X; Zhang, Y; Zhou, Y, 2016
)
0.43
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"We have designed and synthesized 9H-pyrimido[4,5-b]indole-containing compounds to obtain potent and orally bioavailable BET inhibitors."( Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
Bai, L; Hu, Y; Li, S; Li, X; Liu, L; McEachern, D; Meagher, JL; Ran, X; Stuckey, JA; Sun, D; Wang, S; Wen, B; Yang, CY; Zhao, T; Zhao, Y; Zhou, B, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Molibresib (GSK525762), an orally bioavailable small molecule with 2 major equipotent active metabolites, is being developed for the treatment of cancers."( An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
Collins, G; Ferron-Brady, G; Kremer, BE; Patel, A; Riddell, K; Schramek, D; Zhou, Y, 2021
)
0.62
"Molibresib (GSK525762) is an investigational orally bioavailable small-molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors."( Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.
Bergsma, T; Dhar, A; Ferron-Brady, G; Hanze, E; Krishnatry, AS; Prohn, M, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Moreover, hTERT mRNA levels were down-regulated by two BET inhibitors, JQ1 and I-BET762, which at the same dosage (0."( Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.
Allegri, L; Baldan, F; Bulotta, S; Celano, M; Damante, G; Falcone, R; Lepore, SM; Maggisano, V; Maranghi, M; Mio, C; Pecce, V; Rosignolo, F; Russo, D; Sponziello, M; Verrienti, A, 2019
)
0.51
" This model was used to simulate individual patient exposures based on covariate information for use in future alternative dosing strategies and exposure-response analyses."( Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model.
Dhar, A; Ferron-Brady, G; Krishnatry, AS; Prohn, M; Voelkner, A, 2021
)
0.62
" Overall, the PK/PD model (including a maximal drug effect model and molibresib concentration) adequately described platelet counts following molibresib treatment and was used to simulate the impact of molibresib dosing on thrombocytopenia at different doses and regimens."( Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors.
Bergsma, T; Dhar, A; Ferron-Brady, G; Hanze, E; Krishnatry, AS; Prohn, M, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodiazepineA group of heterocyclic compounds with a core structure containing a benzene ring fused to a diazepine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EWS/FLI fusion proteinHomo sapiens (human)Potency4.35570.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)0.22160.00040.40329.0500AID1196538; AID1229997; AID1229998; AID1286395; AID1286396; AID1289189; AID1359742; AID1371238; AID1371243; AID1383780; AID1392193; AID1392194; AID1400167; AID1400168; AID1400169; AID1464711; AID1496253; AID1499131; AID1534669; AID1570965; AID1664717; AID1704653; AID1719442; AID1784030; AID1784031; AID1918626; AID1918627; AID650003; AID692068; AID705339; AID705346; AID731807; AID772237; AID772239; AID773670
Bromodomain-containing protein 4Homo sapiens (human)Ki0.07310.00530.05330.3850AID1229997; AID1229998; AID1371238; AID1371243; AID1535627; AID1535628; AID1535629; AID1565541; AID1565542; AID1632392; AID1632393; AID1632394
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)33.00000.00011.774010.0000AID773629
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)27.69780.00011.753610.0000AID1383780; AID1784034; AID773626
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)33.00000.00002.015110.0000AID773628
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)27.80000.00002.800510.0000AID1196537; AID1784033; AID773630
Bromodomain-containing protein 2Homo sapiens (human)IC50 (µMol)0.36300.00090.53357.4000AID1196536; AID650001; AID692066; AID705341; AID705348
Bromodomain-containing protein 2Homo sapiens (human)Ki0.08250.00050.04470.2200AID1229999; AID1230000; AID1565545; AID1565546
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)33.00000.00002.398310.0000AID773627
Bromodomain-containing protein 3Homo sapiens (human)IC50 (µMol)0.20700.00030.28713.9620AID1196537; AID650002; AID692067; AID705340; AID705347
Bromodomain-containing protein 3Homo sapiens (human)Ki0.06170.00400.02230.0940AID1230001; AID1230002; AID1565543; AID1565544
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Bromodomain-containing protein 4Homo sapiens (human)Kd0.05050.05050.05050.0505AID977611
Bromodomain-containing protein 4Homo sapiens (human)EC50 (µMol)0.44000.00200.16060.4400AID1719443
Bromodomain-containing protein 4Homo sapiens (human)Kd0.05450.00100.36918.9300AID1230007; AID1230008; AID1280130; AID1280131; AID1418203; AID1672368; AID1719449; AID1719450; AID649996; AID705336
Bromodomain-containing protein 2Homo sapiens (human)Kd0.10400.00620.82325.8000AID1230003; AID1230004; AID1280128; AID1280129; AID1719435; AID1719447; AID649994; AID705338
Histone acetyltransferase p300Homo sapiens (human)Kd71.00000.34502.44835.9000AID1719454
Bromodomain-containing protein 3Homo sapiens (human)Kd0.04770.01170.67664.0650AID1230005; AID1230006; AID1719436; AID1719448; AID649995; AID705337
Bromodomain testis-specific proteinHomo sapiens (human)Kd0.08600.02201.00834.8360AID1719451; AID1719452
CREB-binding proteinHomo sapiens (human)Kd46.50003.08406.32809.6000AID1230009; AID1719453
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (132)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
neural tube closureBromodomain-containing protein 2Homo sapiens (human)
nucleosome assemblyBromodomain-containing protein 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 2Homo sapiens (human)
spermatogenesisBromodomain-containing protein 2Homo sapiens (human)
protein localization to chromatinBromodomain-containing protein 2Homo sapiens (human)
chromatin loopingBromodomain-containing protein 2Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
response to hypoxiaHistone acetyltransferase p300Homo sapiens (human)
somitogenesisHistone acetyltransferase p300Homo sapiens (human)
thigmotaxisHistone acetyltransferase p300Homo sapiens (human)
behavioral defense responseHistone acetyltransferase p300Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
regulation of glycolytic processHistone acetyltransferase p300Homo sapiens (human)
protein acetylationHistone acetyltransferase p300Homo sapiens (human)
internal protein amino acid acetylationHistone acetyltransferase p300Homo sapiens (human)
apoptotic processHistone acetyltransferase p300Homo sapiens (human)
canonical NF-kappaB signal transductionHistone acetyltransferase p300Homo sapiens (human)
nervous system developmentHistone acetyltransferase p300Homo sapiens (human)
heart developmentHistone acetyltransferase p300Homo sapiens (human)
skeletal muscle tissue developmentHistone acetyltransferase p300Homo sapiens (human)
learning or memoryHistone acetyltransferase p300Homo sapiens (human)
circadian rhythmHistone acetyltransferase p300Homo sapiens (human)
animal organ morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
negative regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
macrophage derived foam cell differentiationHistone acetyltransferase p300Homo sapiens (human)
regulation of mitochondrion organizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of neuron projection developmentHistone acetyltransferase p300Homo sapiens (human)
N-terminal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
internal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
B cell differentiationHistone acetyltransferase p300Homo sapiens (human)
platelet formationHistone acetyltransferase p300Homo sapiens (human)
lung developmentHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone acetyltransferase p300Homo sapiens (human)
protein destabilizationHistone acetyltransferase p300Homo sapiens (human)
cellular response to nutrient levelsHistone acetyltransferase p300Homo sapiens (human)
cellular response to UVHistone acetyltransferase p300Homo sapiens (human)
multicellular organism growthHistone acetyltransferase p300Homo sapiens (human)
megakaryocyte developmentHistone acetyltransferase p300Homo sapiens (human)
swimmingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of protein import into nucleusHistone acetyltransferase p300Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
response to estrogenHistone acetyltransferase p300Homo sapiens (human)
positive regulation by host of viral transcriptionHistone acetyltransferase p300Homo sapiens (human)
fat cell differentiationHistone acetyltransferase p300Homo sapiens (human)
negative regulation of gluconeogenesisHistone acetyltransferase p300Homo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATHistone acetyltransferase p300Homo sapiens (human)
protein stabilizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone acetyltransferase p300Homo sapiens (human)
face morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine propionylationHistone acetyltransferase p300Homo sapiens (human)
cellular response to L-leucineHistone acetyltransferase p300Homo sapiens (human)
regulation of tubulin deacetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine crotonylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine butyrylationHistone acetyltransferase p300Homo sapiens (human)
regulation of cellular response to heatHistone acetyltransferase p300Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
positive regulation of TORC1 signalingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentHistone acetyltransferase p300Homo sapiens (human)
chromatin organizationBromodomain-containing protein 3Homo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 3Homo sapiens (human)
endodermal cell differentiationBromodomain-containing protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 3Homo sapiens (human)
protein localization to chromatinBromodomain-containing protein 3Homo sapiens (human)
positive regulation of gene expressionBromodomain testis-specific proteinHomo sapiens (human)
chromatin remodelingBromodomain testis-specific proteinHomo sapiens (human)
regulation of DNA-templated transcriptionBromodomain testis-specific proteinHomo sapiens (human)
mRNA processingBromodomain testis-specific proteinHomo sapiens (human)
male meiotic nuclear divisionBromodomain testis-specific proteinHomo sapiens (human)
male meiosis IBromodomain testis-specific proteinHomo sapiens (human)
RNA splicingBromodomain testis-specific proteinHomo sapiens (human)
sperm DNA condensationBromodomain testis-specific proteinHomo sapiens (human)
regulation of RNA splicingBromodomain testis-specific proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain testis-specific proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionATPase family AAA domain-containing protein 2Homo sapiens (human)
transcription initiation-coupled chromatin remodelingATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleosome disassemblyATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleosome assemblyATPase family AAA domain-containing protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (87)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
chromatin bindingBromodomain-containing protein 2Homo sapiens (human)
protein serine/threonine kinase activityBromodomain-containing protein 2Homo sapiens (human)
protein bindingBromodomain-containing protein 2Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 2Homo sapiens (human)
acetylation-dependent protein bindingBromodomain-containing protein 2Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
transcription coregulator bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator bindingHistone acetyltransferase p300Homo sapiens (human)
p53 bindingHistone acetyltransferase p300Homo sapiens (human)
DNA bindingHistone acetyltransferase p300Homo sapiens (human)
chromatin bindingHistone acetyltransferase p300Homo sapiens (human)
damaged DNA bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator activityHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
lysine N-acetyltransferase activity, acting on acetyl phosphate as donorHistone acetyltransferase p300Homo sapiens (human)
protein bindingHistone acetyltransferase p300Homo sapiens (human)
beta-catenin bindingHistone acetyltransferase p300Homo sapiens (human)
zinc ion bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H4 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
nuclear receptor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K18 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H2B acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K27 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
tau protein bindingHistone acetyltransferase p300Homo sapiens (human)
nuclear androgen receptor bindingHistone acetyltransferase p300Homo sapiens (human)
NF-kappaB bindingHistone acetyltransferase p300Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide-lysine-N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
protein propionyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
pre-mRNA intronic bindingHistone acetyltransferase p300Homo sapiens (human)
STAT family protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide 2-hydroxyisobutyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone lactyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetylation-dependent protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone crotonyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3K122 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
chromatin DNA bindingHistone acetyltransferase p300Homo sapiens (human)
chromatin bindingBromodomain-containing protein 3Homo sapiens (human)
protein bindingBromodomain-containing protein 3Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 3Homo sapiens (human)
lncRNA bindingBromodomain-containing protein 3Homo sapiens (human)
molecular condensate scaffold activityBromodomain-containing protein 3Homo sapiens (human)
transcription coactivator activityBromodomain testis-specific proteinHomo sapiens (human)
histone bindingBromodomain testis-specific proteinHomo sapiens (human)
lysine-acetylated histone bindingBromodomain testis-specific proteinHomo sapiens (human)
histone reader activityBromodomain testis-specific proteinHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 2Homo sapiens (human)
histone bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
chromatin bindingATPase family AAA domain-containing protein 2Homo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
chromatinBromodomain-containing protein 2Homo sapiens (human)
nucleusBromodomain-containing protein 2Homo sapiens (human)
nucleoplasmBromodomain-containing protein 2Homo sapiens (human)
cytoplasmBromodomain-containing protein 2Homo sapiens (human)
nuclear speckBromodomain-containing protein 2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
cytoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
nucleusHistone acetyltransferase p300Homo sapiens (human)
nucleoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
chromatinHistone acetyltransferase p300Homo sapiens (human)
protein-DNA complexHistone acetyltransferase p300Homo sapiens (human)
transcription regulator complexHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase complexHistone acetyltransferase p300Homo sapiens (human)
nucleusBromodomain-containing protein 3Homo sapiens (human)
chromatinBromodomain-containing protein 3Homo sapiens (human)
nucleusBromodomain testis-specific proteinHomo sapiens (human)
nucleusATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleoplasmATPase family AAA domain-containing protein 2Homo sapiens (human)
extracellular exosomeATPase family AAA domain-containing protein 2Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 2Homo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (285)

Assay IDTitleYearJournalArticle
AID1383802Inhibition of BRD4 in human TY82 or NCI-H1299 cells assessed as reduction in PD-L1 protein expression at 0.2 to 1 uM after 24 hrs by Western blot analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1672362Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as tumor volume at 40 mg/kg, po QD for 25 days (Rvb = 2189 +/- 604 mm3)2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1672396Drug uptake in tumor tissue of CB17 SCID mouse xenografted with human Kasumi-1 cells at 40 mg/kg, po QD for 25 days and measured after 24 hrs post last dose2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1535619Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD2 bromodomain1 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1672415Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as inhibition of tumor growth at 10 mg/kg, po QD for 29 days2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID773629Inhibition of human CYP1A22013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1918626Inhibition of BRD4 BD2 (unknown origin) measured by TR-FRET assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
AID773655Clearance in rat hepatocytes after 120 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773621Genotoxicity in Salmonella typhimurium TA98 by Ames test in presence of rat S9 mix2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1535626Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged SMARCA4 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID692861Binding affinity to BET2012ACS medicinal chemistry letters, Sep-13, Volume: 3, Issue:9
Bromodomains: are readers right for epigenetic therapy?
AID1286395Inhibition of human His-tagged BRD4 bromodomain 2 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by FRET assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
AID705336Binding affinity to His6-tagged BRD4 expressed in Escherichia coli by isothermal colorimetric analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID773664Fraction unbound in human blood at 1000 ng/ml by equilibrium dialysis method2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1230002Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID773656Clearance in human liver microsomes after 30 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1534669Inhibition of recombinant full length human N-terminal His6-tagged BRD4 (2 to 1362 residues) expressed in baculovirus infected insect cells using histone H4 peptide as substrate by alpha screen assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
AID773650AUC (0 to infinity) in CD rat at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719436Binding affinity to human partial length BRD3-BD1 (P24 to E144 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1400168Inhibition of N-terminal His-tagged BRD4 (BD2) (unknown origin) using biotinylated tetra-acetylated histone H4 peptide after 30 mins by alpha-screen assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
AID1565541Binding affinity to human recombinant BRD4 BD1 (44 to 168 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1719445Stability of compound in human liver microsomes assessed as parent compound remaining after 1 hr2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID773622Genotoxicity in Salmonella typhimurium TA1535 by Ames test in presence of rat S9 mix2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773651AUC (0 to infinity) in beagle dog at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1565548Antiproliferative activity against human MM1S cells assessed as cell growth inhibition after 4 days by CCK8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID773623Genotoxicity in Salmonella typhimurium TA1537 by Ames test in presence of rat S9 mix2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1196537Inhibition of BRD3 (unknown origin) by fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID773637Terminal half life in cynomolgus monkey at 2 mg/kg, iv after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773614Genotoxicity in Escherichia coli WP2uvrA pKM101 by Ames test2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1368370Cytotoxicity against human Loucy cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID1230018Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1368369Cytotoxicity against human 697 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID773662Clearance in mouse liver microsomes after 30 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1784035Metabolic stability in rat hepatocytes assessed as intrinsic clearance per g liver tissue at 0.5 uM measured upto 120 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1229998Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID773616Genotoxicity in Salmonella typhimurium TA98 by Ames test2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1230004Binding affinity to biotinylated BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID706718AUC (infinity) in mouse2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
AID1664717Displacement of APC-labeled biotinylated-avidin from Euphorium-chelated recombinant human N-terminal GST-tagged BRD4 bromodomain 1 expressed in Escherichia coli preincubated for 15 mins followed by APC-labeled biotinylated-avidin addition and measured aft2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
AID772237Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
AID1784031Inhibition of BRD4 in human whole blood assessed as reduction in LPS-induced IL-6 secretion preincubated for 30 mins followed by LPS stimulation and measured after 24 hrs by MSD assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1719435Binding affinity to human partial length BRD2-BD1 (K71 to N194 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1784033Inhibition of recombinant human CYP2C9 expressed in Escherichia coli using FCA as substrate incubated for 15 to 60 mins by fluorometric assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID705339Inhibition of His6-tagged BRD4-BD12 expressed in Escherichia coli assessed as inhibition of binding to SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHGSGSK-biotin after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID773612Passive permeability of the compound2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1230008Binding affinity to biotinylated BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1672363Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as tumor weight at 40 mg/kg, po QD for 25 days (Rvb = 2.57 +/-0.27 g)2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1535624Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain2 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1280130Binding affinity to N-terminal His6-tagged-BRD4 bromodomain 1 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1535625Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged CREBBP assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID773630Inhibition of human CYP2C92013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1464711Inhibition of BRD4 BD1-BD2 (unknown origin) using tetraacetylated histone peptide as substrate after 2 hrs by alphascreen assay2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
AID1230010Binding affinity to biotinylated ATAD2A (981 to 1108 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1672409Toxicity in CB17 SCID mouse xenografted with human Kasumi-1 cells assessed body weight loss at 40 mg/kg, po QD for 25 days2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1280129Binding affinity to full length N-terminal His6-tagged-BRD2 bromodomain 2 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID773653Clearance in cynomolgus monkey hepatocytes after 120 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1784034Inhibition of recombinant human CYP3A4 expressed in Escherichia coli using DEF as probe substrate incubated for 15 to 60 mins by fluorometric assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID692067Displacement of tetra-acetylated H4 peptide from human Brd3 bromodomain BD12 after 1 hr by FRET analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID773663Fraction unbound in dog blood at 1000 ng/ml by equilibrium dialysis method2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773665Fraction unbound in mouse blood at 1000 ng/ml by equilibrium dialysis method2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1196536Inhibition of BRD2 (unknown origin) by fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID1409982Antiproliferative activity against human C4-2B cells after 96 hrs by Cell-Titer glo reagent based luminescence assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
AID773617Genotoxicity in Salmonella typhimurium TA1537 by Ames test2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1418204Cytotoxicity against human MV411 cells after 72 hrs by CellTiter-Glo assay2018Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21
Discovery and lead identification of quinazoline-based BRD4 inhibitors.
AID706719Half life in mouse2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
AID1672411Antiproliferative activity against human Kasumi-1 cells after 72 hrs by Celltiter-Glo assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1280110Binding affinity to BRD2 bromodomain 1 V103A mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID773658Clearance in cynomolgus monkey liver microsomes after 30 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773649AUC (0 to infinity) in cynomolgus monkey at 2 mg/kg, iv and 5 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1383780Displacement of FITC-JQ1 from His6-tagged BRD4 bromodomain-1 (unknown origin) expressed in Escherichia coli BL21(DE3) after 4 hrs by fluorescence anisotropy method2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1280131Binding affinity to N-terminal His6-tagged-BRD4 bromodomain 2 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1535620Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD2 bromodomain2 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1392194Inhibition of BRD4-BD1 in human Raji cells assessed as downregulation of MYC gene expression by PCR method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
AID705340Inhibition of His6-tagged BRD3 expressed in Escherichia coli assessed as inhibition of binding to SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHGSGSK-biotin after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID773641Volume of distribution in cynomolgus monkey at 2 mg/kg, iv and 5 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1371238Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID1368368Cytotoxicity against human NALM16 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID773666Fraction unbound in rat blood at 1000 ng/ml by equilibrium dialysis mehod2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773671Antiinflammatory activity against human PBMC cells assessed as LPS-induced IL-6 production by chemiluminescence assay2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773619Genotoxicity in Escherichia coli WP2uvrA pKM101 by Ames test in presence of rat S9 mix2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773647Blood clearance in CD rat at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1383800Antiproliferative activity against human TY82 cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1632392Displacement of Alexa647-labeled JQ1 derivative from wild type BRD4 tandem domain (44 to 460 residues) (unknown origin) incubated for 1 hr by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).
AID773628Inhibition of human CYP2D62013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID772239Inhibition of His-FLAG-tagged BRD4 binding domain1 (unknown origin) binding to H4-TetraAc-biotin peptide after 20 mins by AlphaLISA2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.
AID1230009Binding affinity to biotinylated CREBBP (1043 to 1159 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1359742Inhibition of BRD4 bromodomain-1 (unknown origin) by FRET assay2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1719444Inhibition of recombinant human ERK5 using myelin basic protein as substrate by [gamm33P]ATP based HotSpot radiometric assay2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1229997Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID705346Inhibition of His6-tagged BRD4 expressed in Escherichia coli after 60 mins by fluorescence anisotropy assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID1392192Half life in mouse liver microsomes2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
AID1565544Binding affinity to human recombinant BRD3 BD2 (306 to 417 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1230001Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1719447Binding affinity to human partial length BRD2-BD2 (E348 to D455 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1371236Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID773632Solubility of the compound in fed state simulated intestinal fluid at pH 6.52013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1286396Inhibition of human His-tagged BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 cells by FRET assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
AID1565580Antitumour activity against human MV4-11 cells xenografted in BALB/c nu/nu mouse assessed as tumour growth inhibition at 60 mg/kg, po via gavage administered once daily for 6 days by vernier caliper method relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1230019Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1280119Binding affinity to BRD2 bromodomain 2 W370F mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID705338Binding affinity to His6-tagged BRD2 expressed in Escherichia coli by isothermal colorimetric analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID1719454Binding affinity to human partial length EP300 (A1040 to G1161 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1535623Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain1 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1652348Antitumor activity against human MCF7:TAM1 cells xenografted in ovariectomized athymic Nude-Foxn1 mouse assessed as tumor growth inhibition at 50 mg/kg/day, po administered via gavage for 4 weeks in presence of fulvestrant2020Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.
AID773613Antiinflammatory activity against po dosed Sprague-Dawley rat immunoinflammatory model assessed as inhibition of KLH-induced ear swelling administered qd for 7 days measured 24 hrs post KLH challenge relative to control2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1280111Binding affinity to BRD2 bromodomain 1 L110I mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID705347Inhibition of His6-tagged BRD3 expressed in Escherichia coli after 60 mins by fluorescence anisotropy assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID1535629Inhibition of tetra-acetylated Histone H4 peptide binding to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain1 after 60 mins by ALPHA screen assay2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID656142Upregulation of ApoA1 expression in human HepG2 cells assessed as concentration required to increase 70% of luciferase activity after 18 hrs by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151.
AID773635Oral bioavailability in CD rat at 3 mg/kg after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1280113Binding affinity to BRD2 bromodomain 1 W097F mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID692068Displacement of tetra-acetylated H4 peptide from human Brd4 bromodomain BD12 after 1 hr by FRET analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID1672361Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as inhibition of tumor growth at 10 mg/kg, po QD for 25 days2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1383799Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1719443Inhibition of BRD4 in human PBMC assessed as reduction in LPS-induced TNFalpha secretion preincubated for 1 hr followed by LPS-stimulation and measured after 20 hrs by magnetic beads technique based assay2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID773652Clearance in human hepatocytes after 120 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1565545Binding affinity to human recombinant BRD2 BD1 (72 to 205 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID650001Displacement of acetylated histone peptide from BRD2-BD1,2 by FRET assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
AID1409984Antiproliferative activity against human 22Rv1 cells after 96 hrs by Cell-Titer glo reagent based luminescence assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
AID692066Displacement of tetra-acetylated H4 peptide from human Brd2 bromodomain BD12 after 1 hr by FRET analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID1704653Displacement of tetra-acetylated Histone H4 peptide from BRD4 (unknown origin) incubated for 1 hr by FRET analysis2020Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23
Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
AID1565546Binding affinity to human recombinant BRD2 BD2 (349 to 460 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID650002Displacement of acetylated histone peptide from BRD3-BD1,2 by FRET assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
AID1565542Binding affinity to human recombinant BRD4 BD2 (333 to 460 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1230005Binding affinity to biotinylated BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID773645Blood clearance in cynomolgus monkey at 2 mg/kg, iv and 5 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719448Binding affinity to human partial length BRD3-BD2 (G306 to P416 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID773625Time-dependent inhibition of human CYP3A42013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1565543Binding affinity to human recombinant BRD3 BD1 (24 to 144 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1409983Antiproliferative activity against human LNCAP cells after 96 hrs by Cell-Titer glo reagent based luminescence assay2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
AID773640Terminal half life in Balb/c mouse at 1 mg/kg, iv after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773639Terminal half life in CD rat at 1 mg/kg, iv after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1368367Cytotoxicity against human NALM6 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID1784037Metabolic stability in human hepatocytes assessed as intrinsic clearance per g liver tissue at 0.5 uM measured upto 120 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1632394Displacement of Alexa647-labeled JQ1 derivative from wild type BRD4 bromodomain 2 (44 to 460 residues) N433A mutant (unknown origin) incubated for 1 hr by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).
AID1280115Binding affinity to N-terminal His6-tagged BRD2 bromodomain 2 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID692056Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID773670Binding affinity to His6-tagged BRD4 (unknown origin) after 60 mins by fluorescence anisotropy binding Assay2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773620Genotoxicity in Salmonella typhimurium TA100 by Ames test in presence of rat S9 mix2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1400167Inhibition of N-terminal His-tagged BRD4 (BD1) (unknown origin) using biotinylated tetra-acetylated histone H4 peptide after 30 mins by alpha-screen assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
AID773642Volume of distribution in beagle dog at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1632393Displacement of Alexa647-labeled JQ1 derivative from wild type BRD4 bromodomain 1 (44 to 460 residues) N140A mutant (unknown origin) incubated for 1 hr by fluorescence polarization assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).
AID649994Binding affinity to BRD2-BD1,2 by isothermal titration calorimetry2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
AID773636Oral bioavailability in Balb/c mouse at 3 mg/kg after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719455Inhibition of IL-6 production in LPS-induced human PBMC preincubated for 1 hr followed by LPS-stimulation and measured after 20 hrs by magnetic beads technique based assay2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1565540Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 4 days by CCK8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1371243Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID731807Binding affinity to human BRD4 1/2 bromodomain by FRET assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
AID773644Volume of distribution in Balb/c mouse at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719456Inhibition of MCP-1 production in LPS-induced human PBMC preincubated for 1 hr followed by LPS-stimulation and measured after 20 hrs by magnetic beads technique based assay2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID773646Blood clearance in beagle dog at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773624Time-dependent inhibition of human CYP2D62013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1383814Antitumor activity against human MM1S cells xenografted in SCID mouse assessed as relative tumor volume at 80 mg/kg, ip administered daily for 21 days relative to control2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1368371Cytotoxicity against human BJ cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID1535628Inhibition of Cy5-linked JQ1 probe binding to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain2 after 60 mins by HTRF assay2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1392196Cytotoxicity against human HL60 cells by MTS assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
AID773661Clearance in rat liver microsomes after 30 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID692058Induction of human ApoA1 protein synthesis in human HepG2 cells assessed as neosynthesised radiolabeled protein secretion after 6 hrs by SDS PAGE analysis in presence of [35S]methionine2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID1383801Inhibition of BRD4 in human TY82 cells assessed as reduction in c-Myc mRNA expression at 0.2 to 1 uM after 24 hrs by RT-PCR analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1230000Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1672369Cytotoxicity against human MV4-11 cells assessed as inhibition of cell viability2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1418203Displacement of biotinylated acetylated peptide from recombinant human partial length BRD4 long isoform bromodomain 1/2 (N44 to E460 residues) expressed in Escherichia coli BL21 measured after 1 hr by Bromoscan method2018Bioorganic & medicinal chemistry letters, 11-15, Volume: 28, Issue:21
Discovery and lead identification of quinazoline-based BRD4 inhibitors.
AID650003Displacement of acetylated histone peptide from BRD4-BD1,2 by FRET assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
AID1383779Inhibition of BRD4 in human TY82 cells assessed as reduction in c-Myc protein expression at 0.2 to 1 uM after 24 hrs by Western blot analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1499132Inhibition of JQ1-FITC binding to His6-tagged BRD4-BD1 (unknown origin) expressed in Escherichia coli BL21 (DE3)-codon plus-RIL cells at 1 uM incubated in dark for 4 hrs by fluorescence anisotropy assay relative to control2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID1565586Selectivity index, ratio of Ki for human recombinant BRD3 BD2 (306 to 417 residues) to Ki for human recombinant BRD3 BD1 (24 to 144 residues)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1230003Binding affinity to biotinylated BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1719453Binding affinity to human partial length CREBBP (R1081 to G1197 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1499131Inhibition of JQ1-FITC binding to His6-tagged BRD4-BD1 (unknown origin) expressed in Escherichia coli BL21 (DE3)-codon plus-RIL cells incubated in dark for 4 hrs by fluorescence anisotropy assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID1400169Inhibition of N-terminal His-tagged BRD4 (BD1/BD2) (unknown origin) using biotinylated tetra-acetylated histone H4 peptide after 30 mins by alpha-screen assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
AID773634Oral bioavailability in cynomolgus monkey at 5 mg/kg after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1368372Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID649995Binding affinity to BRD3-BD1,2 by isothermal titration calorimetry2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
AID1672410Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as tumor volume at 10 mg/kg, po QD for 29 days (Rvb = 1734 +/- 220 mm3)2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID649996Binding affinity to BRD4-BD1,2 by isothermal titration calorimetry2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
AID773626Inhibition of human CYP3A42013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719451Binding affinity to human partial length BRDT-BD1 (N21 to E137 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1535627Inhibition of Cy5-linked JQ1 probe binding to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD4 bromodomain1 after 60 mins by HTRF assay2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID773618Genotoxicity in Salmonella typhimurium TA1535 by Ames test2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719450Binding affinity to human partial length BRD4-BD2 (K333 to E460 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1280114Binding affinity to BRD2 bromodomain 1 W097H mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1672365Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as tumor weight at 10 mg/kg, po administered for 25 days (Rvb = 2.57 +/- 0.27 g)2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1672368Competitive binding affinity to human partial length BRD4 (BD1,2) (N44 to E460 residues) expressed in bacterial expression system by BROMOscan assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID705337Binding affinity to His6-tagged BRD3 expressed in Escherichia coli by isothermal colorimetric analysis2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID1565549Selectivity index, ratio of Ki for human recombinant BRD2 BD1 (72 to 205 residues) to Ki for human recombinant BRD2 BD2 (349 to 460 residues)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1368373Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID773654Clearance in dog hepatocytes after 120 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID705341Inhibition of His6-tagged BRD2 expressed in Escherichia coli assessed as inhibition of binding to SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHGSGSK-biotin after 1 hr by TR-FRET assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID1464713Antiproliferative activity against human THP1 cells2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
AID773627Inhibition of human CYP2C192013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1229999Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1664719Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
AID773660Clearance in dog liver microsomes after 30 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1230007Binding affinity to biotinylated BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1664718Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay2020Bioorganic & medicinal chemistry, 08-01, Volume: 28, Issue:15
Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.
AID1719446Inhibition of human ERG stably expressed in CHO cells at holding potential of -80 mV incubated for 12 mins2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1784030Inhibition of BRD4 in human PBMC assessed as reduction in LPS-induced IL-6 secretion incubated for 18 to 24 hrs by MSD assay2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1565547Selectivity index, ratio of Ki for human recombinant BRD4 BD1 (44 to 168 residues) to Ki for human recombinant BRD4 BD2 (333 to 460 residues)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1784036Metabolic stability in dog hepatocytes assessed as intrinsic clearance per g liver tissue at 0.5 uM measured upto 120 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1719442Inhibition of BRD4-BD1 (unknown origin) by TR-FRET assay2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID773633Oral bioavailability in beagle dog at 3 mg/kg after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773638Terminal half life in beagle dog at 1 mg/kg, iv after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1918627Inhibition of BRD4 BD1 (unknown origin) measured by TR-FRET assay2022Journal of medicinal chemistry, 11-24, Volume: 65, Issue:22
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
AID1570965Inhibition of BRD4 in human MM1S cells assessed as down regulation of c-Myc expression after 1 hr by Western blot analysis2018MedChemComm, Nov-01, Volume: 9, Issue:11
Targeting Brd4 for cancer therapy: inhibitors and degraders.
AID1371237Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.
AID1368366Cytotoxicity against human HD-MB03 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay2018Bioorganic & medicinal chemistry, 01-01, Volume: 26, Issue:1
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
AID773659AUC (0 to infinity) in Balb/c mouse at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773631Solubility of the compound in simulated gastric fluid at pH 1.62013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1535622Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD3 bromodomain2 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID705348Inhibition of His6-tagged BRD2 expressed in Escherichia coli after 60 mins by fluorescence anisotropy assay2012Journal of medicinal chemistry, Jan-26, Volume: 55, Issue:2
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.
AID706902Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
AID1672414Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as tumor weight at 10 mg/kg, po QD for 29 days (Rvb = 2.1+/- 0.3 g)2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1499135Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID1672393Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as tumor volume at 10 mg/kg, po QD for 25 days (Rvb = 2189 +/- 604 mm3)2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1196538Inhibition of BRD4 (unknown origin) by fluorescence anisotrophy2015Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3
Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.
AID773648Blood clearance in Balb/c mouse at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1719449Binding affinity to human partial length BRD4-BD1 (N44 to E168 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1383803Inhibition of BRD4 in human TY82 or NCI-H1299 cells assessed as reduction in PD-L1 mRNA expression at 0.2 to 1 uM after 24 hrs by RT-PCR analysis2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.
AID1280116Binding affinity to BRD2 bromodomain 2 V376A mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID773643Volume of distribution in CD rat at 1 mg/kg, iv and 3 mg/kg, po after 1 hr2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1280109Binding affinity to N-terminal His6-tagged BRD2 bromodomain 1 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1464712Antiproliferative activity against human TY82 cells2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
AID1499136Antiproliferative activity against human TY82 cells after 72 hrs by CCK8 assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID1719452Binding affinity to human partial length BRDT-BD2 (K250 to E382 residues) expressed in bacterial expression system by BROMOscan method2021Bioorganic & medicinal chemistry, 03-15, Volume: 34Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
AID1280117Binding affinity to BRD2 bromodomain 2 L383I mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1496253Inhibition of BRD4 (unknown origin)2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
AID1280120Binding affinity to BRD2 bromodomain 2 W370H mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1565582Toxicity in BALB/c nu/nu mouse xenografted with human MV4-11 cells assessed as decrease in body weight at 60 mg/kg, po via gavage once daily for 6 days and measured every 2 to 3 days relative to control2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1359741Antiproliferative activity against human LNCAP cells2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID773667Solubility of the compound in FaSSIF at pH 6.5 after 16 hrs by HPLC analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID773615Genotoxicity in Salmonella typhimurium TA100 by Ames test2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID1784032Solubility of the compound in FaSSIF at pH 6.5 measured after 30 mins by HPLC analysis2021Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
AID1230006Binding affinity to biotinylated BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1280128Binding affinity to full length N-terminal His6-tagged-BRD2 bromodomain 1 (unknown origin) expressed in competent Escherichia coli BL21(DE3) cells by isothermal titration calorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1392193Inhibition of His-tagged human BRD4-BD1 using H4K5acK8acK12acK16ac as substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by AlphaScreen assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
AID1280118Binding affinity to BRD2 bromodomain 2 L383A mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID1289189Displacement of biotinylated tetra-acetylated histone H4 from human his-tagged BRD4 bromodomain1 by FRET assay2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
AID1280112Binding affinity to BRD2 bromodomain 1 L110A mutant (unknown origin) expressed in competent Escherichia coli DH5-alpha cells using acetylated H4 histone peptide substrate at 10 uM by SYPRO orange staining based differential scanning fluorimetry2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
AID773657Clearance in mouse hepatocytes after 120 mins by LC/MS/MS analysis2013Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
AID692057Induction of human LDL-R gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene at 0.001 to 10 uM after 18 hrs by luminescence assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID1230020Cytotoxicity against human K562 cells harboring BCR-ABL fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1672364Antitumor activity against human Kasumi-1 cells xenografted in CB17 SCID mouse assessed as inhibition of tumor growth at 40 mg/kg, po QD for 25 days2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.
AID1535621Binding affinity to recombinant human N-terminal TEV-cleavable hexa-histidine tagged BRD3 bromodomain1 assessed as change in melting temperature at 30 uM measured after 30 mins by SYPRO orange dye based differential scanning fluorimetry2019Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1345665Human bromodomain containing 4 (Bromodomain kinase (BRDK) family)2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID1346122Human bromodomain containing 3 (Bromodomain kinase (BRDK) family)2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID1345662Human bromodomain containing 2 (Bromodomain kinase (BRDK) family)2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2010Nature, Dec-23, Volume: 468, Issue:7327
Suppression of inflammation by a synthetic histone mimic.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Development of live-cell imaging probes for monitoring histone modifications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (115)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's89 (77.39)24.3611
2020's26 (22.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.29 (24.57)
Research Supply Index4.80 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.42%)5.53%
Reviews4 (3.42%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other109 (93.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]